Diffúz nagy B-sejtes limfóma (DLBCL): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxemburg· EU contribution 216 240 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spanyolország· EU contribution 226 441 EUR· until 2027. jún.

• European Commission (Horizon Europe) · HORIZON-ERC

  Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment (CAR-TIME)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Németország· EU contribution 1 499 875 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

4 of 4 running projects, newest first. Listed amounts together: 2,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 31
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 29
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

• Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B-Cell Lymphoma: A Scoping Review.

  Hematol Oncol, 2026. szept.

• Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

  Blood Adv, 2026. júl.

• MRI Features Associated with Plasma ctDNA Positivity in Central Nervous System Lymphoma.

  Acad Radiol, 2026. máj.

• Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

  J Clin Oncol, 2026. ápr.

• A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.

  Leukemia, 2026. ápr.

• Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.

  BMC Med, 2026. márc.

• Breaking diagnostic and therapeutic barriers in intravascular large B-cell lymphoma: A 13-year real-world study from China.

  Orphanet J Rare Dis, 2026. febr.

• [Future directions in clinical development of first-line therapy for diffuse large B-cell lymphoma].

  Rinsho Ketsueki, 2026. jan.

• Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

  J Clin Oncol, 2025. dec.

• Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.

  Br J Haematol, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.